We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
eHealth (EHTH) Targets 8-10% Adjusted EBITDA Margin by 2025
Read MoreHide Full Article
eHealth, Inc. (EHTH - Free Report) recently hosted an Investor & Analyst Day event in New York, where it revealed its three-year financial targets. While the company expects revenues to grow on the back of its diversification efforts, adjusted EBITDA is likely to witness a $37 million improvement in 2023.
In the revenues front, eHealth expects the metric to grow 6% in 2023 from $405.4 million reported in 2022. Last year, 89% of its revenues came from commissions and in the first quarter of 2023, the figure further increased to 92.2%. The company intends to focus on generating more non-commission revenues, which can lead to higher margins.
Its first quarter revenues declined 30% year over year to $73.7 million. Hence, the company expects a significant turnaround in the coming quarters to achieve the 6% ($420-$440 million range) growth target this year. Further, in the 2024-25 period, it expects to witness 8-10% growth in the top line, per annum.
EBITDA Improvement
For 2023, EHTH expects adjusted EBITDA within a loss of $15 million to a profit of $5 million, the midpoint of which predicts significant improvement from a loss of $42 million in 2022. The company anticipates its cost transformation program to play a major role in returning profits.
By 2025, it intends to achieve 8-10% adjusted EBITDA margin from -10% in 2022. In the first quarter of 2023, it recorded an adjusted EBITDA margin of -17%.
Operating Cash Flow
From operating cash outflow of $13.2 million in the trailing 12-month ended March 2023, it expects to reach the break-even point in the trailing 12-month ending March 2024, backed by a cash collections cycle on MA enrollments. By the trailing 12-month period ending March 2025, the company expects to enter the positive operating cash flow region.
Price Performance
eHealth shares have gained 54.8% in the year-to-date period compared with the 7.6% rise of the industryit belongs to.
The Zacks Consensus Estimate for Allianz’s 2023 earnings is pegged at $2.53 per share, indicating 48% year-over-year growth. Over the past 60 days, ALIZY has witnessed one upward estimate revision against none in the opposite direction.
The Zacks Consensus Estimate for Lemonade’s 2023 earnings suggests 15.9% year-over-year growth. Also, the consensus mark for LMND’s revenues in 2023 suggests a 53.6% year-over-year rise.
The Zacks Consensus Estimate for Argo Blockchain’s 2023 bottom line has improved 47.9% over the past month. During this time, ARBK witnessed two upward estimate revisions against none in the opposite direction.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
eHealth (EHTH) Targets 8-10% Adjusted EBITDA Margin by 2025
eHealth, Inc. (EHTH - Free Report) recently hosted an Investor & Analyst Day event in New York, where it revealed its three-year financial targets. While the company expects revenues to grow on the back of its diversification efforts, adjusted EBITDA is likely to witness a $37 million improvement in 2023.
In the revenues front, eHealth expects the metric to grow 6% in 2023 from $405.4 million reported in 2022. Last year, 89% of its revenues came from commissions and in the first quarter of 2023, the figure further increased to 92.2%. The company intends to focus on generating more non-commission revenues, which can lead to higher margins.
Its first quarter revenues declined 30% year over year to $73.7 million. Hence, the company expects a significant turnaround in the coming quarters to achieve the 6% ($420-$440 million range) growth target this year. Further, in the 2024-25 period, it expects to witness 8-10% growth in the top line, per annum.
EBITDA Improvement
For 2023, EHTH expects adjusted EBITDA within a loss of $15 million to a profit of $5 million, the midpoint of which predicts significant improvement from a loss of $42 million in 2022. The company anticipates its cost transformation program to play a major role in returning profits.
By 2025, it intends to achieve 8-10% adjusted EBITDA margin from -10% in 2022. In the first quarter of 2023, it recorded an adjusted EBITDA margin of -17%.
Operating Cash Flow
From operating cash outflow of $13.2 million in the trailing 12-month ended March 2023, it expects to reach the break-even point in the trailing 12-month ending March 2024, backed by a cash collections cycle on MA enrollments. By the trailing 12-month period ending March 2025, the company expects to enter the positive operating cash flow region.
Price Performance
eHealth shares have gained 54.8% in the year-to-date period compared with the 7.6% rise of the industryit belongs to.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
eHealth currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader finance space are Allianz SE (ALIZY - Free Report) , Lemonade, Inc. (LMND - Free Report) and Argo Blockchain plc (ARBK - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Allianz’s 2023 earnings is pegged at $2.53 per share, indicating 48% year-over-year growth. Over the past 60 days, ALIZY has witnessed one upward estimate revision against none in the opposite direction.
The Zacks Consensus Estimate for Lemonade’s 2023 earnings suggests 15.9% year-over-year growth. Also, the consensus mark for LMND’s revenues in 2023 suggests a 53.6% year-over-year rise.
The Zacks Consensus Estimate for Argo Blockchain’s 2023 bottom line has improved 47.9% over the past month. During this time, ARBK witnessed two upward estimate revisions against none in the opposite direction.